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Abstract : Purpose: The aim of this study
was to observe the effects of and compliance
with an intensive insulin regimen in
preadolescent children with type-1 diabetes.
Patients and methods: Eleven insulindependent diabetic patients, five girls and six
boys aged 8 - 11 years (mean 9 years 3
months) with a mean±SD diabetes duration of
2±1.07 years, participated in this study. The
results of the intensive insulin regimen were
evaluated after one-year follow-up in 11
patients, and in 8 patients at 18 months. In
the first year of this study we aimed to bring
about higher blood glucose than is generally
advised, in order to avoid hypoglycemia. After
one year, we encouraged the patients to promote strict metabolic control.
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Results: Blood glucose and HbA1c levels had
significantly decreased after the intensive
th
insulin regimen at the 12 month of treatment (p<0.05 and p<0.01, respectively), and
th
at the 18 month of treatment (p<0.01 and
p<0.01, respectively). The mean body weight
and mean body mass index (BMI) changes
were insignificant at 12 months (p>0.05), but
had significantly increased at 18 months
(p<0.05 and p<0.01, respectively). None of

the patients experienced symptomatic hypoglycemic episodes during the 12-month follow-up, but severe symptomatic hypoglycemic
episodes were determined at an incidence of
th
th
36% between 12 and 18 months. Diastolic
blood pressure decreased significantly
(p<0.05). Total triglycerides, VLDL triglycerides and total cholesterol as well as LDL cholesterol (LDL-C), VLDL cholesterol (VLDL-C)
and apoprotein B (apo B) decreased (p<0.05)
but high-density lipoprotein cholesterol (HDLC) and apoprotein A1 (apo A1) increased
(p<0.05). The glomerular filtration rate
(GFR) and microalbumin excretion rate did
not change (p>0.05).
Conclusion: Although the patients had no
symptomatic hypoglycemic episodes in the
first 12 months, they had symptomatic hypoth
th
glycemia between 12 and 18 months, when
there was stricter metabolic control. We conclude that this regimen is appropriate for
preadolescent children.
Key Words: Type 1 diabetes mellitus, intensive insulin therapy, multiple injections, preadolescent children

Introduction

Methods

Mortality due to diabetes mellitus has diminished since
the invention of insulin, but morbidity has gradually
increased. Thus, the aim of diabetes treatment has been
to prevent or delay complications. The results of the Diabetes Control and Complications Trial (DCCT) have shown
that the degree of metabolic control obtained in adolescents and adults with type-1 diabetes significantly influences the onset and progression of microvascular complications (1). We examined the effect of an intensive insulin
regimen in preadolescent diabetic patients, an approach
that has not been used with this age group (2,3).

Eleven insulin-dependent diabetic patients aged 8-11
years (mean, 9 years 3 months) followed up at Karadeniz
Technical University Farabi Hospital were included in this
study. The mean duration of the diabetes was 2 ± 1.07
years. The inclusion criteria were failure to respond to
previous treatment (a regimen of twice-daily injections)
and residence close to the hospital. Failure to respond to
treatment was defined as poor metabolic control with a
HbA1c level higher than 9%, daily blood glucose fluctuations higher than 100-150 mg/dL, symptomatic hypoglycemic/hyperglycemic periods, and inadequate adapta-
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tion to treatment in the presence of a conflict between
lifestyle (attendance at school) and the requirements of
conventional treatment. All the patients exhibited normal
growth and development, with no proliferative retinopathy, clinical nephropathy or clinical neuropathy.
The conventional regimen was changed to an intensified insulin therapy, consisting of preprandial short-acting
insulin three times a day and NPH insulin at night.
The blood glucose levels were evaluated four times a
day and two times at night (2 and 4 a.m.) one or two
nights a week. The initial NPH dosage was calculated at
25-30% of the total daily dose, and preprandial crystalline zinc insulin boluses were individualized for each
patient according to meal intake and blood glucose levels.
The glucose levels were maintained within the range
5.55-11.10 mmol/L. The patients were advised to have a
balanced diet containing 50% to 55% carbohydrates,
20% protein, and approximately 30% fat. Calorie intake
was determined according to need, simple sugars were
restricted and a meal-planning program was individualized according to each patient’s family income, lifestyle
and school schedule.
A routine physical examination was performed monthly in the first three months and at 3-month intervals
thereafter. Blood pressure was measured after 15 minutes sitting.
Blood samples were drawn in the morning in the fasting state for serum glucose, HbA1c, creatinine, total cholesterol, HDL cholesterol, LDL cholesterol, VLD cholesterol, total triglyceride, VLDL triglyceride, apo A1, apo B
and anti-insulin antibody. Twenty-four-hour urine samples were collected at 3-month intervals for albumin
excretion rate and glomerular filtration rate. Only the
mean body weight, BMI and HbA1c of eight patients were
evaluated at 18 months.

Initial
(mean ± SD)

Blood samples for plasma lipids and lipoproteins were
also taken from two healthy children for each diabetic
subject so as to serve as sex-age matched controls.
The sample analyses were evaluated as follows:
HbA1c by latex immunoagglutination (Bayer diagnostic);
microalbumin excretion by an immunohistochemical
method (Beckman Assay); glucose, creatinine, triglyceride, VLDL triglyceride, total cholesterol, HDL, LDL and
LDL cholesterol by commercially available enzyme methods (Boehringer Mannheim Biochemicals); apo A1 and
apo B by the Beckman Protein Assay; and anti-insulin
antibody by the RIA method.
BMI was calculated as BMI=weight / height2 and the
glomerular filtration rate (GFR) was calculated as GFR =
K x height / plasma creatinine (K=0.45 for 1-5-year-olds,
0.55 for 5-10-year-olds, 0.55 for adolescent girls and
0.7 for adolescent boys) (4).
Statistical analysis: The results were recorded as the
mean ± SD. For paired samples (before versus after
treatment) the Wilcoxon test was used, and for unpaired
samples (diabetic versus control) the Mann Whitney-U
test was used.

Results
The mean age of our patients was 9 years and 3
months. The mean diabetes duration was two years.
None of the patients had growth retardation or obesity
(mean weight, 27.02 ± 4.66 kg; mean height, 130.37 ±
2
15.06 cm; and mean BMI, 20.18 ± 3.28 kg/m ).
The initial, first month and 12th month mean blood
glucose, HbA1c, insulin dosage and anti-insulin antibody
levels are given in Table 1. Although the insulin dosage
(U/kg) (p>0.05) and antibody-against-insulin levels
(p>0.05) were unchanged, blood glucose levels (p<0.05)

First month
(mean ± SD)

12th month
(mean ± SD)

Blood glucose (mmol/L)

16.13 ± 2.54*a

10.83 ± 1.66

8.38 ± 2.70*b

HbA1c (%)

12.28 ± 0.47

11.84 ± 0.59

9.00 ± 1.45

Insulin dosage (U/kg)
Anti-insulin Ab (%)
*p<0.05 (a, b),
**p<0.01 (c, d)
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0.73 ± 0.04**c
22.22 ± 3.49

0.71 ± 0.21
19.20 ± 3.00

0.65 ± 0.04**d
20.00 ± 4.55

Table 1.

Mean blood glucose, HbA1c,
insulin dosage and insulin antibody
levels.
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After one year of intensive treatment the levels of total
LDL-C and VLDL-C as well as triglycerides, VLDL triglycerides and apolipoprotein B had significantly decreased
(p<0.05). Conversely, the levels of HDL cholesterol, and
apolipoprotein A1 had significantly increased (p<0.05).

and HbA1c levels (p<0.01) had significantly decreased
after the intensive insulin treatment.
The mean albumin excretion rate, GFR, and systolic
and diastolic blood pressure values are given in Table 2.
The GFR and microalbumin excretion rates were
unchanged (p>0.05). Systolic and diastolic blood pressure
were found to have decreased after intensive treatment,
but only the decreased diastolic blood pressure was statistically significant (p<0.05).

After this one-year period, the patients were advised
to promote stricter metabolic control as described previously (5). Eight of the 11 patients were assessed while 3
were withdrawn from the study due to poor compliance.
At the end of the 18th month when compared with the
pretreatment levels, the mean HbA1c of these eight
patients had decreased, to 7.5±1.01 (p<0.01), the mean
body weight and BMI had increased, to 33.20±1.80
2
2
kg/m (p<0.05) and 23.21±1.52 kg/m (p<0.01) respectively, while symptomatic hypoglycemic periods occurred
at an incidence of 36%.

The plasma triglyceride, VLDL triglyceride, total cholesterol, HDL-C, LDL-C, VLDL-C, apo A1 and apo B levels
of the diabetic patients and control group are given in
Table 3. At the beginning of treatment the plasma triglyceride, cholesterol, LDL-C, VLDL-C, apo A1 levels were
higher (p<0.05) and HDL-C, and apo B levels were lower
(p<0.05) in the diabetic group than in the control group.

Initial
(mean±SD)

First month
(mean±SD)

10.52 ± 8.08

13.24 ± 6.70

12th month
(mean±SD)

Table 2.

Twenty four hour urine microalbumin excretion rate, glomerular filtration rate, and systolic and diastolic blood pressure.

Twenty-four-hour urine
Microalbumin (mg/dl)
GFR (ml/sn/1.73)

113.09 ± 23.67

108.9 ± 23.58

10.37 ± 6.35
118.00 ± 14.18

Blood pressure
systolic (mmHg)
diastolic (mmHg)

113.63 ± 2.32
71.36 ± 3.23*a

110.45 ± 2.18

110.53 ± 1.57

65.9 ± 3.00*b

66.42 ± 3.95*c

*p<0.05 (a, b), (b, c)

Table 3.

Mean total plasma triglyceride, VLDL triglyceride, total cholesterol, HDL cholesterol, LDL cholesterol, VLDL cholesterol, apoprotein A1 and
apoprotein B levels of diabetic patients and control group.
Initial
(mean±SD)

Triglyceride (mg/dl)
VLDL triglyceride (mg/dl)
T. cholesterol (mg/dl)
HDL-c (mmol/L)
LDL-c (mmol/L)
VLDL-c(mg/dl)
ApoA1 (mg/dl)
ApoB (mg/dl)
*p<0.05 (a, b),

114.09±52.84a
a

84.09±52.84

a

173.09±31.64
1.06±0.30a
a

2.50±0.63

First month
(mean±SD)

12th month
(mean±SD)

100.27±50.92

90.18±52.15b*

72.24±40.91

29.51±9.82

90.31±33.60c**

b

60.21±22.60c**

b

62.14±34.15 *

163.27±31.39

154.27±55.41 *

147.54±27.23c**

1.12±0.26

1.17±0.34b*

1.21±0.20c**

2.30±0.84

a

Control
(mean±SD)

23.15±11.83

b

2.29±0.88 *

2.27±0.55c**

b

23.10±9.11c**

b

22.11±10.87 *

a

135.20±28.53

130.61±43.40

120.12±21.26 *

114.05±17.31c**

85.53±34.10a

90.09±28.12

96.75±32.28b*

90.15±42.58c**

**p<0.05 (a, c),

p>0.05 (b, c)
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Discussion
Impaired growth is a well-recognized complication of
uncontrolled diabetes (Mauriac syndrome), and less
severe metabolic derangements commonly observed with
conventional treatment may adversely affect growth
potential. Intensive insulin treatment has been shown to
correct metabolic abnormalities and accelerate linear
growth (6). In the present study, all the patients receiving both conventional and intensive treatment had normal
linear growth. Greater weight gain has been reported for
patients treated with one of the intensive insulin regimens
than for patients treated conventionally (7,8). Our results
did not confirm these observations in the first 12 months
of the study, but weight gain was observed between 12
and 18 months.
The blood glucose and HbA1c levels fell significantly
with no difference in the insulin need as in the results of
Nathan et al. (9). Although increased antibody production
against insulin with no significant clinical effects has been
reported (10,11), we did not find any difference between
the anti-insulin antibody levels before and after intensive
treatment.
Hypertension is one of the most important risk factors for initiation and progression of nephropathy and
premature coronary artery disease in diabetic patients.
Although the pre-study blood pressure was not abnormal
and fell within the normal range, the intensive insulin regimen caused blood pressures to decrease further, especially diastolic pressure. Aoki et al. found that tight
glycemic control not only decreased the blood pressure
but also improved the abnormal circadian blood pressure
pattern seen in diabetic patients (12). This observation
supports the view that an intensive insulin regimen tends
to reverse or at least prevent further deterioration of
blood pressure abnormalities.
Microalbuminuria is also a reliable indicator for the
progression of diabetic nephropathy (13-16). lntensive
therapy reduces the cumulative incidence and overall risk
of the development of microalbuminuria and clinical albuminuria (17-19). The expected beneficial effect of the
intensive therapy is to prevent the onset or at least delay
the progression of nephropathy (20). In our study, albuminuria was within normal limits, both in the patients
receiving conventional therapy and in those who underwent a one-year period of intensive therapy. None of the
patients developed microalbuminuria during the follow140

up. Normalization of blood pressure and the prevention
of microalbuminuria might be important factors for the
prevention of chronic diabetic complications such as
nephropathy and coronary artery diseases.
Since insulin has important regulatory effects on plasma lipids and glucose metabolism, plasma lipid and
lipoprotein abnormalities in patients with type-1 diabetes
mellitus change with the absence or presence of insulin
treatment (21-23). The degree of metabolic control in
type-1 diabetes may also influence the lipid and lipoprotein levels. Most studies have shown moderate plasma
lipid and lipoprotein abnormalities in type-1 diabetes
patients treated adequately with conventional insulin
therapy (24,25). With poor control, when insulin administration is subnormal, plasma triglyceride, total cholesterol, LDL-C, VLDL-C, and apo A1 are elevated and HDLC and apo B are decreased. When better metabolic control has been achieved, serum lipid levels return to the
normal levels similar to age- and sex-matched healthy
controls (26). In the present study, we found high cholesterol, VLDL-C, LDL-C, triglyceride,VLDL triglyceride,
apo A1 and low HDL-C and apo B levels in patients treated with a conventional insulin regimen, after treatment
was changed to an intensive insulin regimen. Although we
did not achieve optimal metabolic control, total triglyceride, VLDL triglyceride, cholesterol, VLDL-C, LDL-C, and
apo A1 levels decreased, while HDL-C and apo B levels
increased to the control levels. Since coronary artery disease is one of the most common causes of premature
death in diabetics, secondary hyperlipidemia must be one
of the goals of chronic diabetes treatment in order to prevent arteriosclerosis.
In this study, even though the desired metabolic control was not obtained, some remarkable improvements
were made. First of all, although our patient age group
was very young, the patients easily adapted to the multiple injection therapy because they had more freedom with
regard to meal times than with the conventional regimen.
Moreover, due to decreased diastolic blood pressure, normalized plasma lipid levels and the prevention of microalbuminuria, it is expected that they will have a low risk of
developing complications in the future. In addition, we did
not observe any complications resulting from the intensive insulin therapy, such as severe hypoglycemia or obesity (8,27,28). In the first 12 months, in order to avoid
hypoglycemia the patients were instructed to have higher
target blood glucose levels than those usually reported in
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the literature because of their relatively young ages, but
after the 12th month we observed symptomatic hypoglycemia with strict metabolic control.
Multiple insulin regimens have been widely used
around the world in the past few decades. They are recommended for adolescents and young adults (2,29). This
study shows that a multiple injection regimen can be safely applied in the preadolescent age group.

Correspondence author:
Ayflenur Ökten
KTU Farabi Hospital
Dept. of Pediatrics
61080 Trabzon - TURKEY
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